{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-003357","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.620382+00:00","generated_at":"2026-06-17T21:46:08.354180+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tenax Therapeutics receives US patent for IV levosimendan in PH-HFpEF, expiring Dec 2040","bullets":["U.S. Patent No. 11,607,412 covers IV levosimendan for pulmonary hypertension with HFpEF.","Patent protection extends until December 2040, strengthening IP for levosimendan.","No FDA-approved treatments exist for PH-HFpEF, which affects >1.6M North Americans.","Levosimendan combines K+ATP channel activation and Ca++ sensitization, distinct MoA.","HELP Study showed 29-meter improvement in 6-minute walk distance vs placebo (p=0.03)."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-003357","json":"https://secwatch.observer/filing/0001654954-23-003357.json","markdown":"https://secwatch.observer/filing/0001654954-23-003357.md","text":"https://secwatch.observer/filing/0001654954-23-003357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495423003357/0001654954-23-003357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495423003357/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:46:08.354180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}